Sodium butyrate arrests pancreato-hepatic synchronous uric acid and lipid dysmetabolism in high fat diet fed Wistar rats

Adeyanju, O.; Badejogbin, Olabimpe C.; Areola, D.E; Olaniyi, Kehinde S.; Dibia, Chinaza; Soetan, Olaniyi; Oniyide, Adesola A.; Michael, Olugbenga Samuel; Olatunji, Lawrence Aderemi; Soladoye, Ayodele O.

doi:10.1016/j.biopha.2020.110994

Cited by 30 publications

(15 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These adipocyte interactions highlight that in vivo studies need to be conducted in order to investigate the effects of butyrate on adipose tissue in context of other tissues (as they may affect one another). In obese rodent models, chronic butyrate treatment attenuated diet‐induced elevations in systemic lipid profiles including triglycerides and cholesterol 155,181,187,188,190,191,238 . These improved lipid markers hint towards enhanced adipose tissue storage capacity but may also be the result of improved liver functioning (or both).…”

Section: Mechanistic Underpinning: Butyrate and Interorgan Crosstalkmentioning

confidence: 99%

“…In obese rodent models, chronic butyrate treatment attenuated diet-induced elevations in systemic lipid profiles including triglycerides and cholesterol. 155,181,187,188,190,191,238 These improved lipid markers hint towards enhanced adipose tissue storage capacity but may also be the result of improved liver functioning (or both). Human crosssectional data showed that fasting plasma butyrate levels were negatively associated with plasma FFA levels.…”

Section: Butyrate and Adipose Tissue Metabolismmentioning

confidence: 99%

“…Butyrate might be able to prevent pancreatic dysfunction associated with the insulinresistant obese phenotype. Animal data indicate that butyrate may increase insulin secretion 161,177,187 and reduce pancreatic fat deposition and β-cell damage, thereby preserving islet functioning 161,187,190,219,238 (see Figure 3). Several studies have shown that chronic butyrate treatment decreased fasting insulin levels in T2DM rats 260 and obese rodents 156,177,183,191,238 compared with their respective controls.…”

Section: Butyrate and Pancreatic Insulin Functioningmentioning

confidence: 99%

“…Animal data indicate that butyrate may increase insulin secretion 161,177,187 and reduce pancreatic fat deposition and β-cell damage, thereby preserving islet functioning 161,187,190,219,238 (see Figure 3). Several studies have shown that chronic butyrate treatment decreased fasting insulin levels in T2DM rats 260 and obese rodents 156,177,183,191,238 compared with their respective controls. One of these studies showed that acute butyrate administration rapidly increased insulin release compared with a saline control, whereas the same dose of other fatty acids including acetic acid did not significantly alter insulin secretion.…”

Section: Butyrate and Pancreatic Insulin Functioningmentioning

confidence: 99%

See 3 more Smart Citations

Butyrate to combat obesity and obesity‐associated metabolic disorders: Current status and future implications for therapeutic use

2022

View full text Add to dashboard Cite

Evidence is increasing that disturbances in the gut microbiome may play a significant role in the etiology of obesity and type 2 diabetes. The short chain fatty acid butyrate, a major end product of the bacterial fermentation of indigestible carbohydrates, is reputed to have anti-inflammatory properties and positive effects on body weight control and insulin sensitivity. However, whether butyrate has therapeutic potential for the treatment and prevention of obesity and obesity-related complications remains to be elucidated. Overall, animal studies strongly indicate that butyrate administered via various routes (e.g., orally) positively affects adipose tissue metabolism and functioning, energy and substrate metabolism, systemic and tissue-specific inflammation, and insulin sensitivity and body weight control. A limited number of human studies demonstrated interindividual differences in clinical effectiveness suggesting that outcomes may depend on the metabolic, microbial, and lifestyle-related characteristics of the target population. Hence, despite abundant evidence from animal data, support of human data is urgently required for the implementation of evidence-based oral and gut-derived butyrate interventions. To increase the efficacy of butyrate-focused interventions, future research should investigate which factors impact treatment outcomes including baseline gut microbial activity and functionality, thereby optimizing targeted-interventions and identifying individuals that merit most from such interventions.

show abstract

Section: Mechanistic Underpinning: Butyrate and Interorgan Crosstalkmentioning

confidence: 99%

Section: Butyrate and Adipose Tissue Metabolismmentioning

confidence: 99%

Section: Butyrate and Pancreatic Insulin Functioningmentioning

confidence: 99%

Section: Butyrate and Pancreatic Insulin Functioningmentioning

confidence: 99%

See 2 more Smart Citations

Butyrate to combat obesity and obesity‐associated metabolic disorders: Current status and future implications for therapeutic use

2022

View full text Add to dashboard Cite

show abstract

“…From a metabolism point of view, lipid dysmetabolism is closely related to an increased risk of the metabolic syndromes such as NAFLD, NASH, and obesity. 9,25,26 In this study, lipid accumulation in the liver was observed in NAFLD mice shown with significant elevation in the levels of hepatic SFA, MUFA, and PUFA. Consistently, mRNA levels of hepatic lipid synthesis genes including Scd1, Fasn, and Acaca were markedly increased in NAFLD mice.…”

Section: ■ Discussionmentioning

confidence: 99%

Structural Insights into Amelioration Effects of Quercetin and Its Glycoside Derivatives on NAFLD in Mice by Modulating the Gut Microbiota and Host Metabolism

Shi

Zhang

Lei

et al. 2022

J. Agric. Food Chem.

View full text Add to dashboard Cite

The sugar moieties of natural flavonoids determine their absorption, bioavailability, and bioactivity in humans. To explore structure-dependent bioactivities of quercetin, isoquercetin, and rutin, which have the same basic skeleton linking different sugar moieties, we systemically investigated the ameliorative effects of dietary these flavonoids on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) of mice. Our results revealed that isoquercetin exhibits the strongest capability in improving NAFLD phenotypes of mice, including body and liver weight gain, glucose intolerance, and systemic inflammation in comparison with quercetin and rutin. At the molecular level, dietary isoquercetin markedly ameliorated liver dysfunction and host metabolic disorders in mice with NAFLD. At the microbial level, the three flavonoids compounds, especially isoquercetin, can effectively regulate the gut microbiota composition, such as genera Akkermansia, Bifidobacterium, and Lactobacillus, which were significantly disrupted in NAFLD mice. These comparative findings offer new insights into the structure-dependent activities of natural flavonoids for NAFLD treatment.

show abstract

Acetate-mediated-obestatin modulation attenuates adipose-hepatic dysmetabolism in high fat diet-induced obese rat model

et al. 2022

View full text Add to dashboard Cite

Sodium butyrate arrests pancreato-hepatic synchronous uric acid and lipid dysmetabolism in high fat diet fed Wistar rats

Cited by 30 publications

References 47 publications

Butyrate to combat obesity and obesity‐associated metabolic disorders: Current status and future implications for therapeutic use

Butyrate to combat obesity and obesity‐associated metabolic disorders: Current status and future implications for therapeutic use

Structural Insights into Amelioration Effects of Quercetin and Its Glycoside Derivatives on NAFLD in Mice by Modulating the Gut Microbiota and Host Metabolism

Acetate-mediated-obestatin modulation attenuates adipose-hepatic dysmetabolism in high fat diet-induced obese rat model

Contact Info

Product

Resources

About